Delivery Order SPE2DB22D2005-SPE2DB25FJRD3
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Xcopri 100 mg tablets (30-count units) valued at $3,536.88. This is a firm fixed-price delivery order with no set-aside designation, classified as a competitive award. The contract has an ultimate completion date of August 11, 2025, and performance will be executed at AmerisourceBergen's Corporate Office facility in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Xcopri 50 mg tablets (30-count) with a ceiling value of $2,070.10. This competitive award utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The contract carries no set-aside designation, indicating it...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,221.54 to AmerisourceBergen Drug Corp for the supply of Xcopri 100 mg tablets (30-count packages) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $2,569.42 on July 28, 2025, for Xcopri 50 mg tablets (30-count supply). This is a firm fixed-price delivery order with no set-aside designation, representing a competitively awarded contract under the company's existing pharmaceutical supply agreements with DLA. The order will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Xcopri 150 mg tablets (30-count units) with a ceiling value of $1,178.96. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The contract was competitively awarded without set-aside designation and is scheduled for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Xcopri 25 mg tablets (30-unit packaging), with a contract ceiling value of $1,768.44. This is a firm fixed price delivery order with an ultimate completion date of August 14, 2025, and represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child...
- The Defense Logistics Agency awarded a $2,357.92 delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Xcopri 25 mg tablets (30-count). This competitively awarded, firm fixed-price contract carries an ultimate completion date of August 6, 2025, and represents a child order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The contract involves no set-aside designation and identifies Conshohocken, Pennsylvania, as the place of performance,...
- The Defense Logistics Agency awarded a delivery order valued at $3,660.38 to AmerisourceBergen Drug Corp for 30 tablets of Xcopri 100 mg on August 11, 2025, with an ultimate completion date of August 12, 2025. This non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a $2,232.99 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 30 tablets of Xcopri 200 mg on July 28, 2025, with completion targeted for July 29, 2025. This non-set-aside contract represents a pharmaceutical supply delivery to support federal medical procurement needs, with performance occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award is issued as a child contract under AmerisourceBergen's...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on August 5, 2025, by the Defense Logistics Agency for the supply of Xcopri 100 mg tablets (30-count package) with a ceiling value of $4,846.14. This competitively awarded, firm fixed-price delivery order is set to be completed by August 6, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- SPE2DB22D2005Indefinite Delivery Contract
- SPE2DB22D2005-SPE2DB25FJRD3Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Xcopri 100 mg tablets in quantities of 30 units, with a ceiling value of $2,357.92 and an ultimate completion date of August 11, 2025. This competitively awarded, non-set-aside contract utilized firm fixed price pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under AmerisourceBergen Drug Corp's significant $999,999,999.00 Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, which extends through December 2026 and serves as a comprehensive global pharmaceutical support vehicle. The underlying IDC enables the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains for customers including the Defense Health Agency and U.S. Coast Guard. Xcopri, an anticonvulsant medication, falls within the neurological treatments category that AmerisourceBergen routinely delivers through this framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.4k | 8/8/25 |